AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7767194
Drug: Hyperbaric chamber
RxNorm normalized name: HOLDING CHAMBER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric chamber treatment at 193 mbar for 1 hour
Trial: 2312782
Drug: Quinidine sulfate
RxNorm normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulfate 200 mg orally every 8 hours for 24 hours prior to antipyrine administration
Trial: 2312782
Drug: Antipyrine 1
RxNorm normalized name: antipyrine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipyrine 1 gram dose alone
Trial: 6774845
Drug: 4580 rad
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4580 rad in 10 treatments, 11 days overall
Trial: 16278522
Drug: Thiazide-type diuretics
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide-type diuretics
Trial: 31628783
Drug: ABP 710
RxNorm normalized name: ABPC
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABP 710 (5 mg/kg intravenously over 2 hours)
Trial: 31628783
Drug: Infliximab US
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab US (5 mg/kg intravenously over 2 hours)
Trial: 31628783
Drug: Infliximab EU
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab EU (5 mg/kg intravenously over 2 hours)
Trial: 29390538
Drug: Reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy (35 to 45 minutes, 2 times/week for 12 weeks)
Trial: 29390538
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug therapy only
Trial: 20496741
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with bloodletting therapy
Trial: 20496741
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with western medicine (e.g., catgut embedding therapy with Fluoxetine, electroacupuncture with Seroxat)
Trial: 17688075
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (40 mg pantoprazole enteric coated tablets) under fasting condition
Trial: 17688075
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (40 mg pantoprazole enteric coated tablets) under fasting condition
Trial: 17688075
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (40 mg pantoprazole enteric coated tablets) under fed condition
Trial: 17688075
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (40 mg pantoprazole enteric coated tablets) under fed condition
Trial: 26999644
Drug: Higher hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Higher hydrocortisone dose (0.4-0.6 mg/kg body weight)
Trial: 26999644
Drug: Lower hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lower hydrocortisone dose (0.2-0.3 mg/kg body weight)
Trial: 21810288
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose oat beta-glucan (30g beta-glucan; oats high - OH)
Trial: 21810288
Drug: Low-dose oat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose oat beta-glucan (1.5 g beta-glucan; oats low - OL)
Trial: 21810288
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose oat beta-glucan (30g beta-glucan; oats high - OH) in responders
Trial: 17581195
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of IL-5 (10 microg via nebulizer)
Trial: 23952947
Drug: Other antihypertensive
RxNorm normalized name: Other antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihypertensive drugs
Trial: 1290631
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination screening (first round)
Trial: 1290631
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination screening (second round)
Trial: 6147451
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement group
Trial: 18805677
Drug: SSRI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI treatment
Trial: 30138013
Drug: Treatment remission
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment remission
Trial: 9695995
Drug: Ribavirin alone
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin alone (1,000 mg/daily for 6 months) followed by interferon alfa n‐3 alone (3 MU thrice weekly for 6 months)
Trial: 9695995
Drug: Ribavirin plus
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin plus interferon alfa n‐3 for 6 months at the above doses
Trial: 9695995
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa n‐3 alone (3 MU thrice weekly for 6 months)
Trial: 31485457
Drug: Vildagliptin plus
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin plus low-dose metformin (VLDM)
Trial: 31485457
Drug: High-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metformin (HDM)
Trial: 26735057
Drug: Closed-suction drains
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Closed-suction drains in the subcutaneous tissue
Trial: 22156332
Drug: Single-dose pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single-dose pregabalin (150 mg before surgery)
Trial: 15363813
Drug: Night-time graded-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night-time graded-release diltiazem (GRD) 360 mg
Trial: 15363813
Drug: Morning amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning amlodipine 5 mg
Trial: 12972704
Drug: Neoadjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant systemic chemotherapy
Trial: 10604299
Drug: Topical carteolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical carteolol hydrochloride 1.0%
Trial: 7577850
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg daily for 8 weeks, then 400 mg for 16 weeks)
Trial: 7577850
Drug: Gestrinone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone (2.5 mg twice a week for 24 weeks)
Trial: 2036187
Drug: Dexamethasone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (single intravenous dose)
Trial: 31250761
Drug: Viola odorata
RxNorm normalized name: VIOLA ODORATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viola odorata L. oil (20 drops) applied to the peripheral margin of the umbilicus
Trial: 31250761
Drug: Viola odorata
RxNorm normalized name: VIOLA ODORATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viola odorata L. oil
Trial: 19900993
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus metformin (2000 mg)
Trial: 19900993
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus repaglinide (6 mg)
Trial: 17893258
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II type 1 receptor blockade (losartan 200 mg) during hyperinsulinaemic euglycaemic clamp (AT-HEC)
Trial: 27603954
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate placebo (3 g day-1)
Trial: 23390066
Drug: 12-session reality
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-session reality therapy drug treatment program
Trial: 24620447
Drug: Triple-drug therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug therapy (OM 40/AML 10/HCTZ 25 mg)
Trial: 24620447
Drug: Dual therapies
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapies (OM 40/AML 10 mg, OM 40/HCTZ 25 mg, AML 10/HCTZ 25 mg)
Trial: 1858154
Drug: Triple-drug therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug therapy
Trial: 24620447
Drug: Dual therapies
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapies
Trial: 22503212
Drug: Cinacalcet 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet 100 mg
Trial: 17323180
Drug: Daily bisphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bisphosphonate (alendronate 10 mg/day or risedronate 5 mg/day)
Trial: 9663484
Drug: Anti-TNFalpha monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-TNFalpha monoclonal antibody treatment
Trial: 8174061
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy (HFX) with brachytherapy; HFX doses of 1.2 Gy administered twice daily, total dose to the whole pelvis 24-48 Gy, followed by one or two intracavitary applications to deliver a total minimum dose of 85 Gy at point A and 65 Gy to lateral pelvic nodes.
Trial: 2883990
Drug: Topical levobunolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical levobunolol 0.5%
Trial: 2883990
Drug: Topical metipranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical metipranolol 0.6%
Trial: 8746886
Drug: New chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New chemotherapy
Trial: 27860366
Drug: Intranasal sodium
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sodium citrate (1 mL)
Trial: 27860366
Drug: Physiological sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological sodium chloride solution (1 mL, internal control)
Trial: 21486801
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (arginase inhibition plus L-arginine)
Trial: 11387588
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program (twice weekly group exercise)
Trial: 3115372
Drug: HIV counselling
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV counselling and antibody testing during the campaign periods
Trial: 3115372
Drug: HIV counselling
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV counselling and antibody testing
Trial: 17184491
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg twice daily for 8 weeks
Trial: 7814635
Drug: Lipopeptide-based therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipopeptide-based therapeutic vaccine (5 and 50 micrograms)
Trial: 2108855
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg rt-PA plus heparin over 4 h
Trial: 2108855
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg rt-PA over 8 h, repeated in 24 h
Trial: 2900919
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus heparin
Trial: 2108855
Drug: 4-h infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-h infusion of rt-PA
Trial: 465276
Drug: Rapid release
RxNorm normalized name: Mapap Rapid Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid release oxprenolol (160 mg)
Trial: 788749
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release oxprenolol (160 mg)
Trial: 29980388
Drug: Belief that
RxNorm normalized name: Ora Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belief that the vaccine is safe
Trial: 28965384
Drug: Phloroglucinol combined
RxNorm normalized name: phloroglucinol
DrugBank: Phloroglucinol (DB12944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloroglucinol combined with parecoxib (80 mg phloroglucinol qd plus 40 mg parecoxib bid for 3 days)
Trial: 28965384
Drug: Phloroglucinol only
RxNorm normalized name: phloroglucinol
DrugBank: Phloroglucinol (DB12944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloroglucinol only (80 mg phloroglucinol qd for 3 days)
Trial: 17345837
Drug: levocetirizine 5
RxNorm normalized name: Levocetirizine 5mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levocetirizine 5 mg
Trial: 375838
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no low-dose heparin)
Trial: 31761458
Drug: No game,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No game, oral information at the outpatient clinic, current standard of care (Group C)
Trial: 19543129
Drug: Bazedoxifene 20
RxNorm normalized name: bazedoxifene 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 20 mg
Trial: 21435024
Drug: Blue light
RxNorm normalized name: Ocuvite Blue Light Mini Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue light treatment, three times weekly for four weeks
Trial: 22079052
Drug: Intraoral myofascial
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoral myofascial therapy plus education and self-care exercises (IMTESC)
Trial: 18701270
Drug: Azithromycin (AZM)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZM) 500 mg for 20-29 kg, 750 mg for 30-39 kg, 1000 mg for 40-49 kg, 1250 mg for >50 kg once a week for 8 weeks
Trial: 17664376
Drug: Pravastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin treatment
Trial: 28589472
Drug: Ca(OH)2 +
RxNorm normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca(OH)2 + 2% chlorhexidine (CHX) gel for 7 days
Trial: 28589472
Drug: Ca(OH)2 +
RxNorm normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca(OH)2 + saline solution (SSL) for 14 days
Trial: 24722260
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg over 10 minutes followed by a continuous infusion of 0.5 μg/kg/h throughout surgery)
Trial: 12424553
Drug: LI 160
RxNorm normalized name: LIS-1
DrugBank: LIS-1 (DB18388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LI 160 (600 mg/day)
Trial: 8577017
Drug: Delayed parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed parenteral nutrition (PN) at day 5, n = 5
Trial: 31950384
Drug: Supportive-expressive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive group therapy (SEGT) combined with oncologic treatment (BRBC)
Trial: 30771790
Drug: N-acetyl-cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-cysteine (NAC) 600 mg/d for 3 months
Trial: 21967242
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention (hypoglycemic and antihypertensive agents)
Trial: 21967242
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents)
Trial: 21967242
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents, and vitamin E)
Trial: 21967242
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents, and compound salvia tablets)
Trial: 15469774
Drug: Raloxifene (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (pooled doses)
Trial: 9840853
Drug: 5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL/kg of 0.35% lidocaine with 1:1,000,000 epinephrine
Trial: 9840853
Drug: 5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL/kg of saline with 1:1,000,000 epinephrine
Trial: 2684698
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel (2 mg)
Trial: 2684698
Drug: PGE2 tablet
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 tablet (3 mg)
Trial: 30807822
Drug: Lung dose
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung dose ≥800 cGy
Trial: 30807822
Drug: Lung dose
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung dose <800 cGy
Trial: 25257861
Drug: Intravenous elemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous elemental iron (40 mg) administered at all three hemodialysis sessions in the first week (IW1 group: n=57)
Trial: 25257861
Drug: Intravenous elemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous elemental iron (40 mg) administered in the third week (IW3 group: n=53)
Trial: 22717454
Drug: Etrolizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab (0.5 mg/kg SC, n=4)
Trial: 22717454
Drug: Etrolizumab (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab (3.0 mg/kg SC, n=4)
Trial: 22717454
Drug: Etrolizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab (all doses in MD stage)
Trial: 12556011
Drug: G-CSF and
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF and antibiotic therapy (n=8)
Trial: 8849475
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with antibiotics for POD
Trial: 8849475
Drug: MRI three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI three months after treatment
Trial: 7006558
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amitriptyline and IPT
Trial: 31278280
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside (NR) 100 mg
Trial: 31278280
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside (NR) 300 mg
Trial: 31278280
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside (NR) 1000 mg
Trial: 31277780
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography (LDCT)
Trial: 20031380
Drug: Nut diet
RxNorm normalized name: Coconut diethanolamide
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nut diet (30 g/day of raw nuts)
Trial: 3978008
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no infusion)
Trial: 7867675
Drug: BAY x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY x 7195 250 mg
Trial: 2670019
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (ESTRADERM TTS‐50), 50 micrograms/day